Navigation Links
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
Date:12/1/2011

ROCKVILLE, Maryland and SURESNES, France, Dec. 1, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an option for a license agreement for the development and commercialization of MGA271, MacroGenics' proprietary product candidate.  MGA271 is a first-in-class, Fc-optimized monoclonal antibody that targets B7-H3 and is currently being studied in a Phase 1 clinical trial for the treatment of solid tumors.

MGA271 is a next generation monoclonal antibody which incorporates multiple complementary mechanisms of action including enhanced immuno-stimulatory properties and targeting of tumor vasculature. The B7-H3 target is overexpressed in several malignancies requiring innovative therapeutic approaches.  "Following very promising pre-clinical results, we will work together to define the clinical indications and the best drug combinations and to identify early biomarkers predictive of response," said Stephane Depil, M.D., Ph.D., in charge of Oncology Research & Development at Servier. "Today's announcement underscores Servier's commitment to develop novel targeted therapies that address significant unmet medical needs for cancer patients," added Emmanuel Canet, M.D., Ph.D., President Research & Development at Servier. "MGA271 is a novel immunotherapeutic with a compelling product profile and the potential to treat a broad spectrum of solid tumors. We have been deeply impressed by both the excellence of science being conducted by MacroGenics and their world-class antibody development capabilities. We are looking forward to building a long-term strategic collaboration with MacroGenics."

Under the terms of the agreement, MacroGenics retains full development and commercialization rights to MGA271 in the U.S., Canada, Mexico, Japan, Korea and India, whil
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
2. MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
3. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
4. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
5. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
6. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
7. Intercept Pharmaceuticals and Servier Announce Agreement for Intercepts TGR5 Research Program in Type 2 Diabetes
8. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
9. Zimmer to Establish Asia-Pacific Research and Development Center
10. vRad Selected by Abbeville Area Medical Center for PACS Replacement
11. ETCs Aircrew Training Systems Completes Factory Acceptance Tests for Highly Advanced Suite of Training Equipment for the Republic of Korea Air Force Aeromedical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... New York, NY (PRWEB) , ... September 01, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – today announced its annual Light it Red for Lymphoma awareness ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted the 18th ... Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn in each ... whom work for Calvary, and two junior counselors who were campers themselves just a ...
(Date:9/1/2015)... ... , ... Georgia State University and its partners have introduced ... sexual assaults on their campuses. , The free, evidence-based survey was developed by ... and student affairs professionals responding to calls by the Obama Administration to strengthen ...
(Date:9/1/2015)... ... 2015 , ... As part of its ongoing commitment to ... (Blue Cross) has announced Doctor On Demand as the company’s preferred telehealth service ... provides immediate access to Board Certified physicians or next-day appointments with psychologists from ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia ... Machine,” is still strongly maintaining her firm’s success in the hair care and ... her upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
... ... services, recently partnered with the Arthritis Foundation to provide community outreach and education on ... from arthritis. , ... Oak Brook, IL (Vocus) June 1, 2009 -- Arthritis is one of the most ...
... ... have forced healthcare providers, insurers, and managed care organizations to take a hard look at ... now changes. Instead of "Do I accommodate the LEP market?" we are asking, "How do ... , ...
... Bethesda, MD (June 1, 2009) Obesity is an ... the presence of additional risk factors further increases the ... new study in Clinical Gastroenterology and Hepatology , ... Institute. , Obesity has become an epidemic in the ...
... time intestinal inflammation with systemic chromosome damage in mice, ... and treatment of human inflammatory disorders, some of which ... found that local intestinal inflammation induced DNA damage to ... This means that chromosome damage was not limited to ...
... on Major Health Policy IssuesMENLO PARK, Calif., June 1 ... reform debate and the ongoing financial turmoil in the ... Health News (KHN) today to provide a new source ... is staffed by experienced health policy journalists and editors, ...
... locates California medical practice,s oldest ,test-tube baby;, Three of America,s ... RAMON, Calif., May 31 Elizabeth Castro Wilson, who on ... the East San Francisco Bay Area, will join two other ... helped create them, when the Reproductive Science Center ...
Cached Medicine News:Health News:AthletiCo Physical Therapy Partners with Arthritis Foundation 2Health News:AthletiCo Physical Therapy Partners with Arthritis Foundation 3Health News:Avantpage Translations Releases White Paper on Capturing The Fastest Growing Healthcare Market In America 2Health News:Obesity predicts inadequate bowel prep at colonoscopy 2Health News:UCLA cancer researchers first to link intestinal inflammation with systemic chromosome damage 2Health News:UCLA cancer researchers first to link intestinal inflammation with systemic chromosome damage 3Health News:Kaiser Family Foundation Launches New Non-Profit Health Policy News Service 2Health News:Kaiser Family Foundation Launches New Non-Profit Health Policy News Service 3Health News:Kaiser Family Foundation Launches New Non-Profit Health Policy News Service 4Health News:Kaiser Family Foundation Launches New Non-Profit Health Policy News Service 5Health News:Found: First IVF Baby Born in East Bay 25 Years Ago 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: